The Risk of Thrombosis in Patients with Lupus Anticoagulants Is Predicted by their Specific Coagulation Profile

Summary

Lupus anticoagulants belong to the family of antiphospholipid antibodies. They include two phospholipid-dependent inhibitors of coagulation that may be distinguished on the basis of specific coagulation profiles generated from the comparison of the ratios of the Kaolin Clotting Time (KCT) and the dilute Russell’s Viper Venom Time (dRVVT): when the ratio of the KCT exceeds that of the dRVVT, the plasma is allocated to the “KCT” coagulation profile, when the opposite occurs, the plasma is defined to belong to the “dRVVT” coagulation profile group. We prospectively followed-up a historical cohort of 100 consecutive patients with lupus anticoagulants referred to our Institution between January 1988 and October 1997 to investigate the relationship between their coagulation profile at diagnosis and the development of thrombosis during a median follow-up time of 37.5 months (range 1-115 months). Fifty-six patients were allocated to the “dRVVT” coagulation profile, whereas the other 44 displayed the “KCT” profile. Lupus anticoagulants were transient in 17 patients, without differences between the two groups. None of these patients developed clinical events before disappearance of the phospholipid-dependent inhibitors of coagulation. The 83 cases with persistent lupus anticoagulants consistently displayed the same coagulation profile they had been allocated to at entry. Fourteen patients developed 18 thromboembolic events during the follow-up, with an overall rate of thrombosis of 4.2% patients-year. Twelve of them belonged to the “dRVVT” coagulation profile, whereas the other 2 to the “KCT” profile (p = 0.03). The “dRVVT” coagulation profile gave an odds ratio of thrombosis of 5.25 (95% confidence interval [C.I.]: 1.17-23.50). Ten of the 14 patients who developed thrombosis during follow-up had already experienced thrombosis: a previous thrombotic event caused an odds ratio of recurrency of 2.72 (95% C.I.: 0.85-8.73) (p = 0.09). By multivariate analysis, the “dRVVT” coagulation profile was still associated with a trend to a higher risk of thrombosis, but the difference did not reach statistical significance. Increased levels of anticardiolipin antibodies (> 40 GPL and/or MPL units) were found in all the 14 patients (p = 0.0064). The “KCT” coagulation profile was significantly associated (p = 0.005) with moderate thrombocytopenia (platelets 50-150 × 10⁹/l). Neither profile was found to represent a risk factor for the development of recurrent miscarriages, neoplastic diseases and death. In conclusion, the “dRVVT” profile appears to have predictive value with respect to the thrombotic complications suffered by patients with antiphospholipid antibodies.

• References

• 1 Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA).. Thromb Haemost 1995; 74: 329-37.
• 2 Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Roddi E, Baudo F, Manotti C, D’Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.. Am J Med 1996; 100: 530-6.
• 3 Galli M, Finazzi G, Barbui T. “Antiphospholipid antibodies”: predictive value of laboratory tests.. Thromb Haemost 1997; 78: 75-8.
• 4 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.. Thromb Haemost 1991; 66: 629-32.
• 5 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of α₂-Glycoprotein I is potentiated by a distinct subgroup of anti-cardiolipin antibodies.. Thromb Haemost 1992; 68: 297-300.
• 6 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin Clotting Time and dilute Russell’s viper venom time distinguish between prothrombin- and α_2-glycoprotein I-dependent antiphospholipid antibodies.. Blood 1995; 86: 617-23.
• 7 Norbis F, Barbui T, Galli M. Dilute Russell’s Viper Venom Time and Colloidal Silica Clotting Time for the identification of the phospholipid-dependent inhibitors of coagulation.. Thromb Res 1997; 85: 427-31.
• 8 Galli M, Ruggeri M, Barbui T. Differential effects of anti-α₂-glycoprotein I and anti-prothrombin antibodies on the anticoagulant activity of activated protein C.. Blood 1998; 91: 1999-2004.
• 9 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.. Thromb Haemost 1995; 74: 1185-90.
• 10 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.. Br J Haematol 1978; 40: 143-51.
• 11 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants.. Blood 1986; 68: 869-74.
• 12 Triplett DA, Stocker KF, Unger GA, Barna LK.. The textarin/ecarin ratio: a confirmatory test for lupus anticoagulant. Thromb Haemost 1993; 70:: 925-31.
• 13 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosor-bent assay: standardization and quantitation of results.. Clin Exp Immunol 1985; 62: 738-44.
• 14 Harris EN, Gharavi AE, Hughes GRV. The anticardiolipin assay. In Harris EN, Exner T, Hughes GRV, Asherson RA. (eds). Phospholipid-binding antibodies. Boca Raton: CRC Press; 1991: 175-87.
• 15 Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus.. Thromb Haemost 1996; 76: 916-24.
• 16 Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus.. J Rheumatol 1998; 25: 1104-9.
• 17 Kunke A, Bertolaccini ML, Atsumi T, Amengual O, Khamashta MA, Hughes GRV. Autoantibodies to prothrombin-phosphatidylserine complex: clinical significance in systemic lupus erythematosus.. Lupus 1998; 7 (Suppl. 02) suppl S 221 (abstract B74).
• 18 Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-α₂-glycoprotein I than with antiphospho-lipid antibodies.. J Rheumatol 1995; 22: 1899-906.
• 19 Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeclik A. Anticardiolipin, anti-α₂-glyco-protein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.. J Rheumatol 1997; 24: 1710-5.
• 20 Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants.. Thromb Haemost 1995; 74: 1120-5.
• 21 Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies.. Thromb Haemost 1996; 75: 721-5.
• 22 Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies.. Thromb Haemost 1997; 77: 486-91.
• 23 Palosuo T, Virtamo J, Taylor PR, Aho K, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men.. Thromb Haemost 1997; 78: 1178-83.
• 24 Martinuzzo ME, Forastiero RR, Carreras LO. Anti α₂ glycoprotein I antibodies: detection and association with thrombosis.. Br J Haematol 1995; 89: 397-402.
• 25 Day HM, Thiagarajan P, Ahn C, Reveilee JD, Tinker KF, Arnett FC. Auto-antibodies to α₂-glycoprotein I in systemic lupus erythematosus and primary antiphopsholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody test.. J Rheumatol 1998; 25: 667-74.
• 26 Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies.. Thromb Haemost 1994; 71: 571-5.
• 27 Foster WM, Triplett DA, Barna LK. Evaluation of 7 dilute Russell viper venom time (dRVVT) kits.. Lupus 1994; 3: 351 (abstr 155).
• 28 Norbis F, Barbui T, Galli M. Comparison of two Russell’s viper venom time (dRVVT) for distinguishing the phospholipid-dependent inhibitors of coagulation.. Thromb Haemost. 1997. 331 suppl abstr 1356
• 29 Callahan JB, Manares CC, Moll S, Ortel TL. Inability to distinguish between thrombotic and non-thrombotic antiphospholipid antibody positive patients with kaolin clotting time and dilute Russell’s viper venom assay ratio.. Lupus 1996; 5: 530 (abstract 111).